MRNS Research and Charts

MRNS - Marinus Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-01-03)

Last 0.54	Change ⇑ +0.01 (+0.00%)	Volume 1,259,238
	Open 0.53	High 0.54	Low 0.52

8EMA (Daily) 0.45	40EMA (Daily) 0.45	50EMA (Daily) 0.52	STO (Daily) 97.500	MACD Hist (Daily) 0.099
8EMA (Weekly) 0.426	40EMA (Weekly) 1.98	50EMA (Weekly) 2.51	STO (Weekly) 5.869	MACD Hist (Weekly) 0.222


Company Profile
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.